Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and
associated mortality than the general population. Owing to this increased risk, patients with …

Background Available data show that COVID-19 vaccines may be less effective in
immunocompromised populations, who are at increased risk of severe COVID-19 …

Abstract Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune
monitoring (CAPTURE)(NCT03226886) is a prospective cohort study of COVID-19 immunity …

Background B-cell-depleting therapies increase the risk of morbidity and mortality due to
COVID-19. Evidence-based SARS-CoV-2 vaccination strategies for patients on B-cell …

Patients with cancer experience a higher burden of SARS-CoV-2 infection, disease severity,
complications, and mortality, than the general population. SARS-CoV-2 mRNA vaccines are …

Background Patients with cancer have an increased risk of complications from SARS-CoV-2
infection. Vaccination to prevent COVID-19 is recommended, but data on the …

COVID-19 mRNA vaccines are highly efficacious in preventing COVID-19 morbidity and
mortality in phase 3 clinical studies as well as in real-world settings. Emerging evidence …

The coronavirus infectious disease (COVID-19) shows a remarkable symptomatic
heterogeneity. Several risk factors including advanced age, previous illnesses, and a …

Background Patients with cancer are considered a priority group for Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccination given their high risk of …

Patients with chronic lymphocytic leukemia (CLL) have an impaired antibody response to
coronavirus disease 2019 (COVID-19) vaccination. Here, we evaluated the antibody …